426 related articles for article (PubMed ID: 32965597)
1. LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.
Cao Y; Zhang F; Wang H; Bi C; Cui J; Liu F; Pan H
Mol Cell Biochem; 2021 Jan; 476(1):279-292. PubMed ID: 32965597
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
[TBL] [Abstract][Full Text] [Related]
3. Long Non-Coding MALAT1 Functions as a Competing Endogenous RNA to Regulate Vimentin Expression by Sponging miR-30a-5p in Hepatocellular Carcinoma.
Pan Y; Tong S; Cui R; Fan J; Liu C; Lin Y; Tang J; Xie H; Lin P; Zheng T; Yu X
Cell Physiol Biochem; 2018; 50(1):108-120. PubMed ID: 30278452
[TBL] [Abstract][Full Text] [Related]
4. lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC.
Li Z; Wu G; Li J; Wang Y; Ju X; Jiang W
BMC Cancer; 2020 Apr; 20(1):282. PubMed ID: 32252678
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma.
Ma J; Li T; Han X; Yuan H
J Cancer Res Clin Oncol; 2018 Feb; 144(2):205-214. PubMed ID: 29127494
[TBL] [Abstract][Full Text] [Related]
6. Long Noncoding RNA MALAT1 Regulates Hepatocellular Carcinoma Growth Under Hypoxia via Sponging MicroRNA-200a.
Zhao ZB; Chen F; Bai XF
Yonsei Med J; 2019 Aug; 60(8):727-734. PubMed ID: 31347327
[TBL] [Abstract][Full Text] [Related]
7. LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis.
Wang D; Zhang S; Zhao M; Chen F
Cancer Med; 2020 Dec; 9(23):9138-9149. PubMed ID: 33146951
[TBL] [Abstract][Full Text] [Related]
8. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
9. LncRNA HCG11 accelerates the progression of hepatocellular carcinoma via miR-26a-5p/ATG12 axis.
Li ML; Zhang Y; Ma LT
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10708-10720. PubMed ID: 31858580
[TBL] [Abstract][Full Text] [Related]
10. LncRNA CDKN2BAS predicts poor prognosis in patients with hepatocellular carcinoma and promotes metastasis via the miR-153-5p/ARHGAP18 signaling axis.
Chen J; Huang X; Wang W; Xie H; Li J; Hu Z; Zheng Z; Li H; Teng L
Aging (Albany NY); 2018 Nov; 10(11):3371-3381. PubMed ID: 30510148
[TBL] [Abstract][Full Text] [Related]
11. LncRNA CYTOR affects the proliferation, cell cycle and apoptosis of hepatocellular carcinoma cells by regulating the miR-125b-5p/KIAA1522 axis.
Hu B; Yang XB; Yang X; Sang XT
Aging (Albany NY); 2020 Dec; 13(2):2626-2639. PubMed ID: 33318318
[TBL] [Abstract][Full Text] [Related]
12. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
[TBL] [Abstract][Full Text] [Related]
13. Circ_0003998 enhances doxorubicin resistance in hepatocellular carcinoma by regulating miR-218-5p/EIF5A2 pathway.
Li X; He J; Ren X; Zhao H; Zhao H
Diagn Pathol; 2020 Dec; 15(1):141. PubMed ID: 33308276
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA MALAT1 regulates proliferation, apoptosis, migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer.
Song J; Su ZZ; Shen QM
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1853-1862. PubMed ID: 32141554
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA CRNDE promotes malignant progression of hepatocellular carcinoma through the miR-33a-5p/CDK6 axis.
Lin C; Xiang Y; Sheng J; Liu S; Cui M; Zhang X
J Physiol Biochem; 2020 Aug; 76(3):469-481. PubMed ID: 32621257
[TBL] [Abstract][Full Text] [Related]
17. RNF185-AS1 promotes hepatocellular carcinoma progression through targeting miR-221-5p/integrin β5 axis.
Huang C; Li K; Huang R; Zhu J; Yang J
Life Sci; 2021 Feb; 267():118928. PubMed ID: 33358902
[TBL] [Abstract][Full Text] [Related]
18. LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells.
Bai T; Liu Y; Li B
IUBMB Life; 2019 Oct; 71(10):1537-1551. PubMed ID: 31188543
[TBL] [Abstract][Full Text] [Related]
19. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
[TBL] [Abstract][Full Text] [Related]
20. LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis.
Sun DS; Guan CH; Wang WN; Hu ZT; Zhao YQ; Jiang XM
Microvasc Res; 2021 Mar; 134():104120. PubMed ID: 33309645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
